Idiopathic Pulmonary Fibrosis Market Growth Driven by Next-Gen Therapies and Targeted Treatments

The idiopathic pulmonary fibrosis (IPF) market is driven by companies such as Hoffmann-La Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore Pharma. Next-generation therapies, including targeted treatments and biologic therapies, are being developed to slow disease progression and potentially reverse lung damage. The high prevalence of IPF in an aging population and improved diagnosis are driving the need for effective treatments and new therapeutic options.